cvl006
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 20, 2024 (NCT06621615)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07157956 | Phase 1/Phase 2 (Phase 2) | Sep 10, 2025 | Convalife, Sun Yat-Sen University |
| NCT06621615 | Phase 1 | Nov 20, 2024 | China Pharmaceutical University, Convalife |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Convalife | For profit | 2 | 2 | 2 | 2024 |
| China Pharmaceutical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1